IL304219A - Parts for extending half-life and methods of using them - Google Patents

Parts for extending half-life and methods of using them

Info

Publication number
IL304219A
IL304219A IL304219A IL30421923A IL304219A IL 304219 A IL304219 A IL 304219A IL 304219 A IL304219 A IL 304219A IL 30421923 A IL30421923 A IL 30421923A IL 304219 A IL304219 A IL 304219A
Authority
IL
Israel
Prior art keywords
methods
same
life extending
extending moieties
moieties
Prior art date
Application number
IL304219A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL304219A publication Critical patent/IL304219A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
IL304219A 2021-02-02 2023-07-03 Parts for extending half-life and methods of using them IL304219A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144696P 2021-02-02 2021-02-02
PCT/US2022/014728 WO2022169757A1 (en) 2021-02-02 2022-02-01 Half-life extending moieties and methods of using the same

Publications (1)

Publication Number Publication Date
IL304219A true IL304219A (en) 2023-09-01

Family

ID=80735776

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304219A IL304219A (en) 2021-02-02 2023-07-03 Parts for extending half-life and methods of using them

Country Status (18)

Country Link
US (1) US20240316154A1 (cg-RX-API-DMAC10.html)
EP (1) EP4288452A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024506145A (cg-RX-API-DMAC10.html)
KR (1) KR20230137342A (cg-RX-API-DMAC10.html)
CN (1) CN116802209A (cg-RX-API-DMAC10.html)
AU (1) AU2022217754A1 (cg-RX-API-DMAC10.html)
CA (1) CA3204225A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023002285A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023010002A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230366A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000149A (cg-RX-API-DMAC10.html)
EC (1) ECSP23058246A (cg-RX-API-DMAC10.html)
IL (1) IL304219A (cg-RX-API-DMAC10.html)
JO (1) JOP20230173A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009006A (cg-RX-API-DMAC10.html)
PE (1) PE20240233A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022169757A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202306754B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260109751A1 (en) * 2022-12-30 2026-04-23 Eli Lilly And Company Methods of dulaglutide purification using hydrophobic interaction chromatography
EP4731669A2 (en) * 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259802A1 (en) * 2008-03-31 2010-12-15 Glaxo Group Limited Drug fusions and conjugates
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2015231170B2 (en) * 2014-03-20 2019-10-03 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3807311A4 (en) * 2018-04-24 2022-01-26 National Research Council of Canada SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法

Also Published As

Publication number Publication date
PE20240233A1 (es) 2024-02-16
ECSP23058246A (es) 2023-09-29
CO2023010002A2 (es) 2023-09-08
JP2024506145A (ja) 2024-02-09
KR20230137342A (ko) 2023-10-04
CR20230366A (es) 2023-10-03
CN116802209A (zh) 2023-09-22
ZA202306754B (en) 2025-02-26
JOP20230173A1 (ar) 2023-07-30
CL2023002285A1 (es) 2024-02-23
AU2022217754A1 (en) 2023-07-27
DOP2023000149A (es) 2023-09-15
CA3204225A1 (en) 2022-08-11
EP4288452A1 (en) 2023-12-13
WO2022169757A1 (en) 2022-08-11
MX2023009006A (es) 2023-08-08
CL2025003008A1 (es) 2025-12-19
US20240316154A1 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
IL299760A (en) Radiopharmaceuticals and methods
PT3872091T (pt) Anticorpos contra sars-cov-2
IL276331A (en) An orientation tool with improved flexibility and traceability
IL286079B2 (en) History of Imidazolonylquinilines and their medical uses
IL305834A (en) Phenalkylamines and methods for their preparation and use
GB2591554B (en) Composiitons and methods and uses relating thereto
IL304736A (en) Binders and methods of using them
IL284994A (en) Pyrrolopyrimidine derivative and its use
IL290217B2 (en) Communication system and its use
PL3861219T3 (pl) Środki łączące i mebel je zawierający
GB2589437B (en) Circuitry and methods
PL3774141T3 (pl) Hydrauliczny uchwyt rozprężny i jego zastosowanie
GB202015044D0 (en) New compounds and methods
GB202009064D0 (en) Compounds and methods of use
AU2022217754A9 (en) Half-life extending moieties and methods of using the same
IL285572A (en) pic1 variants with improved solubility and methods of using them
PL3921565T3 (pl) Element wtykowy i zastosowanie elementu wtykowego
EP3996786A4 (en) RESPIRATORY ASSEMBLY AND METHODS OF USE
IL288828A (en) Binding factors - cd38 and their use
GB202103872D0 (en) Uses and methods
GB202007928D0 (en) New uses and methods
HK40096247A (en) Half-life extending moieties and methods of using the same
IL311521A (en) Compounds targeting EGFRVIII and their uses
GB202106040D0 (en) Methods and uses
GB202019660D0 (en) Uses and methods